Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target - Terms Include up to $200 million in Potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results